Edition:
United Kingdom

Ultragenyx Pharmaceutical Inc (RARE.OQ)

RARE.OQ on NASDAQ Stock Exchange Global Select Market

44.02USD
14 Dec 2017
Change (% chg)

$-1.17 (-2.59%)
Prev Close
$45.19
Open
$45.30
Day's High
$45.79
Day's Low
$43.86
Volume
115,525
Avg. Vol
161,893
52-wk High
$91.17
52-wk Low
$43.44

Select another date:

Mon, Dec 4 2017

BRIEF-Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab In X-Linked Hypophosphatemia

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE POSITIVE 48-WEEK DATA FROM ADULT PHASE 3 STUDY OF BUROSUMAB (KRN23) IN X-LINKED HYPOPHOSPHATEMIA Source text for Eikon: Further company coverage:

BRIEF-Ultragenyx completes patients dosing in first cohort of phase 1/2 study of DTX301

* Ultragenyx announces completion of patient dosing in first cohort of phase 1/2 clinical study of dtx301 gene therapy in ornithine transcarbamylase (OTC) deficiency

BRIEF-ULTRAGENYX SAYS FDA APPROVES MEPSEVII FOR GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

* ULTRAGENYX ANNOUNCES FDA APPROVAL OF MEPSEVII™ (VESTRONIDASE ALFA), THE FIRST THERAPY FOR PROGRESSIVE AND DEBILITATING RARE GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

FDA approves Ultragenyx drug for rare enzyme disorder

The U.S. Food and Drug Administration approved on Wednesday a new treatment made by Ultragenyx Pharmaceutical Inc for a rare genetic disorder that can dramatically reduce life expectancy.

UPDATE 1-U.S. FDA approves Ultragenyx drug for rare enzyme disorder

Nov 15 The U.S. Food and Drug Administration approved on Wednesday a new treatment made by Ultragenyx Pharmaceutical Inc for a rare genetic disorder that can dramatically reduce life expectancy.

BRIEF-FDA approves Ultragenyx Pharmaceutical's Mepsevii for rare genetic enzyme disorder‍​

* Approved Ultragenyx Pharma's Mepsevii to treat pediatric, adult patients with inherited metabolic condition called mucopolysaccharidosis TYPE VII ‍​ Further company coverage:

BRIEF-Ultragenyx reports third quarter 2017 financial results

* Ultragenyx Pharmaceutical Inc- ‍cash, cash equivalents, and investments were $396.0 million as of September 30, 2017​

BRIEF-Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

* Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

BRIEF-ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION

* ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION

BRIEF-Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 mln-SEC filing

* Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 million-SEC filing

Select another date: